Headquartered in Baltimore, MD with ties to Johns Hopkins but also having research facilities in Puerto Rico, CDI Laboratories, Inc. (CDI) is a biotechnology company delivering products and services founded on whole human proteome microarray technology. The companyâs products and services are designed to overcome great hurdles that are currently slowing down advancements in the proteomics field in the areas of research, and protein-based therapeutics and diagnostics. CDI has a series of patent-pending platform technologies that are allowing the company to develop novel products, to provide unparalleled services and offer accelerating partnership opportunities. In January 2023 it was announced that BroadOak Capital Partners had acquired CDI Laboratories for an undisclosed amount
